New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare
(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm
Read More
Part D/Prescription Drugs
340B reporting mandate approved by House subcommittee, legislation moves forward
(By Ashleigh Hollowell for Becker’s hospital Review) Legislation proposing transparency and oversight of the 340B drug discount program was passed
Read MorePBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
(By Arthur Allen for KFF Health News) For two decades, patients and physicians eagerly awaited a lower-cost version of the
Read MoreEli Lilly says an experimental drug slows Alzheimer’s worsening
(Source -The Associated Press published May 4, 2023 by NPR) WASHINGTON — Eli Lilly and Co. said Wednesday its experimental
Read More26 state attorneys general urge Medicare to cover Alzheimer’s treatments
(By Rylee Wilson for Becker’s Hospital Review) Twenty-six state attorneys general are asking Medicare to cover monoclonal antibody treatments for
Read MoreHalf of All Eligible Medicare Beneficiaries Are Now Enrolled in Private Medicare Advantage Plans
(By Jeannie Fuglesten Biniek, Meredith Freed, Anthony Damico, and Tricia Neuman for Kaiser Family Foundation published May 01, 2023) According
Read MoreMore enrollees choosing higher-premium Medicare Advantage, Part D plans
(Rylee Wilson for Becker’s Hospital Review) The average premium cost for Medicare Advantage plans sold on eHealth increased from $6
Read MoreAHIP, AHA point fingers on cost of specialty drugs
(By Rylee Wilson for Becker’s Hospital Review) Insurer groups say hospitals are to blame for higher costs of specialty drugs,
Read MoreHospitals will spend up to 3% more on drugs in 2023, study finds
(By Paige Twenter for Becker’s Hospital Review) Nonfederal hospitals’ costs have hovered around $35 billion to $40 billion since 2018,
Read MoreMedicare to cover new Alzheimer’s drugs, Eli Lilly says
(By Jakob Emerson for Becker’s Hospital Review) Eli Lilly is expecting CMS to reverse course on its Medicare coverage policies
Read More